Plumbline Life Sciences, Inc.
A KONEX-listed animal-health biotech that commercialized ReNewDog, a canine DNA aging treatment, and develops porcine DNA immunomodulators.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2014, listed on KONEX in 2015, Plumbline Life Sciences develops animal DNA therapeutics based on Inovio Pharmaceuticals technology. It commercialized ReNewDog(TM), a canine healthy-aging treatment, and pursues out-licensing of LifeTide(R) SW5, a porcine DNA immunomodulator, plus an African Swine Fever (ASF) vaccine. It targets China, about 50% of the global pig population.
Products & technology
- ReNewDogHealthy-aging treatment for companion dogs
- LifeTide® SW5DNA immunomodulator for pigs
R&D and key agreements
Source: DART corporate disclosure아프리카돼지열병(ASF) 백신 · 아프리카돼지열병 예방 · 개발·공급 추진 · Planned development and supply targeting the China market
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition